Management of Castration Resistant Prostate Cancer

From the book reviews: This volume in the Current Clinical Urology series focuses on the management of castration resistant prostate cancer (CRPC), providing an important reference for medical oncologists, urologists, and radiation oncologists. The authors successfully update the biology and clinical aspects of CRPC management. This book sets out the most current knowledge about the management of CRPC, a fascinating area in clinical urology. It should be part of the library of any clinician or basic scientist dealing with prostate cancer. (Jianqing Lin, Doodys Book Reviews, November, 2014)

Fred Saad, MD, FRCS Professor and Chief of Urology, Director of GU Oncology, University of Montreal Endowed Chair in Prostate Cancer, University of Montreal Hospital Center, Department of Surgery, Division of Urology, Montreal, Quebec, Canada. Mario A. Eisenberger, MD R. Dale Hughes Professor of Oncology and Urology, The Johns Hopkins University, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.

Introduction - Castration Resistant Prostate Cancer: A Rapidly Expanding Clinical State and a Model for New Therapeutic Opportunities.- Evolution of Clinical States and the Castration Resistant Clinical Paradigm.- Molecular Mechanisms of Prostate Cancer Progression after Castration.- New Imaging Modalities.- Androgen Receptor Biology in Castration Resistant Prostate Cancer.- The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer.- Approaches Targeting Androgen Synthesis (CYP 17 inhibitors).- Cytotoxic Chemotherapy (Taxanes and Taxane Combinations).- The Emerging Role of Immunotherapy in Castrate Resistant Prostate Cancer.- Bone Targeted Therapy: Rationale and Current Status.- Radium-223 and Other Radiopharmaceuticals in Prostate Cancer.- Introduction.- Phase I/II targeted treatments.- Defining Clinical Endpoints in Castration-resistant Prostate Cancer.- Angiogenesis Inhibition in Castration Resistant Prostate Cancer.- Co-targeting Adaptive Survival Pathways.- Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer.- PARP Inhibitors.- Targeting C-Met/VEGF in Castration Resistant Prostate Cancer.- Epigenetics in Castration Resistant Prostate Cancer.- Undifferentiated Prostate Cancer and the Neuroendocrine Phenotype.- Strategies Addressing Quality of Life: Patient Reported Outcome and Symptoms Management.- Evidence-Based Therapeutic Approaches for mCRPC patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development.